Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
J Clin Apher ; 36(4): 628-633, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1748739

ABSTRACT

BACKGROUND: Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. AIMS: This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. MATERIALS & METHODS: Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. RESULTS: The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre-operative desensitization and efficacy for treatment of post-operative patients. No immediate hemolytic transfusion reaction was reported. DISCUSSION: While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. CONCLUSIONS: Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.


Subject(s)
ABO Blood-Group System , Blood Group Incompatibility/therapy , Plasma Exchange/methods , Transplantation/methods , Agglutinins/chemistry , Blood Banks/supply & distribution , Graft Survival , Hemolysis , Humans , Kidney Transplantation/adverse effects , Patient Safety , Plasma/immunology , Plasmapheresis , Transfusion Reaction , Treatment Outcome
2.
4.
Cell Tissue Bank ; 21(4): 557-562, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-871503

ABSTRACT

On March 19 World Health Organization declare the pandemic situation by outbreak coronavirus disease 2019 in the world. The pressure on the health care system has been very high in several countries. Spanish National Transplant Organization (ONT) have made many efforts in maintaining transplantation activity. Although the impact of the pandemic on organ activity has been analysed, to date, less data exist regarding the impact on tissue activity. The aim of this study has been the evaluation of the possible impact on the procurement, processing and distribution of tissues during the peak period of the pandemic COVID-19 in Spain. For this study, a multicentre analysis has been made with a survey of the tissue banks in Spain, during the period March 1 to April 30, 2020. Our data suggest that the impact of coronavirus in Spain has affected dramatically tissue donation but with a moderate effect on stored tissues such as bone, valves, vessels or skin. Tissue banks should prepare if future next pandemic waves surges so that tissue provision is guaranteed both in urgent and elective surgeries.


Subject(s)
Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Tissue Banks/statistics & numerical data , Tissue and Organ Procurement/statistics & numerical data , Transplantation/statistics & numerical data , Betacoronavirus , COVID-19 , Humans , Pandemics , SARS-CoV-2 , Spain/epidemiology , Surveys and Questionnaires
6.
Rev. colomb. cir ; 35(2): 227-234, 2020000.
Article in Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-664643

ABSTRACT

Durante los primeros meses de la pandemia por SARS-CoV 2 (Coronavirus 2 del Síndrome Respiratorio Agudo y Grave), el agente etiológico de la Enfermedad Infecciosa por Coronavirus de 2019 (COVID-19), la actividad de donación y trasplante de órganos en todo el mundo se ha visto claramente afectada. Las principales razones que en este momento motivan el cese parcial o total de los trasplantes son: 1) la carga asistencial que genera el manejo de un potencial donante en la Unidad de Cuidado Intensivo (UCI), 2) el alto riesgo de contagio entre donante y receptor, 3) el riesgo de inmunosuprimir a un paciente en medio de la pandemia y 4) la escasez de camas de UCI. A pesar de que el mundo está enfrentando a una enfermedad emergente que merece especial atención, al mismo tiempo continúan prevaleciendo las complicaciones asociadas a las demás enfermedades, incluyendo las complicaciones de patologías crónicas en estado terminal. La decisión de continuar con los programas de trasplante se debe basar en el comportamiento local del virus y en la capacidad asistencial de cada una de las instituciones. En Colombia, el comportamiento epidemiológico del SARS-CoV 2 varía significativamente entre las diferentes regionales, permitiendo a las instituciones que hasta el momento presentan poca carga de atención del COVID-19 retomar sus actividades de trasplante. De esta manera se propone un balance entre mantener las medidas de prevención y atención del COVID-19 y continuar ofreciendo los servicios de trasplante, principalmente a los pacientes con alto riesgo de morbi-mortalidad en lista de espera


The SARS-CoV2 (Severe Acute Respiratory Syndrome­related to Coronavirus 2) pandemic, which is the etiological agent of the Coronavirus Infectious Disease 2019 (COVID-19), organ donation and transplantation activity throughout the world has been clearly affected. The main reasons that currently motivate the partial or total cessation of transplants are: 1) the burden of care burden generated by the management of a potential donor in the Intensive Care Unit (ICU), 2) the high risk of donor/recipient viral transmission, 3) the risk of using immuno-suppressing a patient in the midst of the pandemic, and 4) the shortage of ICU beds. Despite the fact that the world is facing an emerging disease that deserves special attention, at the same time the complications associated with other diseases continue to prevail, including complications of end-stage chronic diseases. The decision to continue with the transplant programs should be based on the local behavior of the virus and the healthcare capacity of each of the institutions. In Colombia, the epidemiological behavior of SARS-CoV2 varies significantly between different regions, allowing institutions that, until now, have little burden of attention from COVID-19, to resume their transplant activities. In this way, a balance is proposed between maintaining the prevention and care measures of COVID-19 and continuing to offer transplant services mainly to patients with a high risk of morbidity and mortality on the waiting list


Subject(s)
Humans , Coronavirus Infections , General Surgery , Transplantation , SARS Virus
7.
Rev. colomb. cir ; 35(2): 216-226, 2020000. tab
Article in Spanish | WHO COVID, LILACS (Americas) | ID: covidwho-664642

ABSTRACT

Es grande la expectativa que genera en todos los servicios de salud del mundo la rápida expansión del SARS-CoV2 (Coronavirus 2 del Síndrome Respiratorio Agudo y Grave), agente etiológico de la Enfermedad Infec-ciosa por Coronavirus del año 2019, COVID-19. Por tratarse de una enfermedad emergente es poco lo que se conoce sobre su comportamiento en los humanos, lo que lleva a múltiples interrogantes al momento de tomar decisiones en la práctica clínica. Hasta el momento, las estrategias para enfrentar esta pandemia se basan en la experiencia de los países que han sido epicentro del brote infeccioso y en la evidencia recopilada durante el manejo de otros coronavirus en años anteriores (SARS-CoV en el año 2002 y MERS-CoV en 2012). La falta de información contundente y unificada ha dado lugar a especulaciones y a suposiciones, especialmente relacionadas con la atención del COVID-19 en poblaciones consideradas de alto riesgo, como son los pacientes crónicamente inmunosuprimidos postrasplante. A través de esta revisión narrativa de la literatura, más allá de dar la opinión de los autores, se pretende organizar de manera juiciosa los documentos hasta el momento publicados, y responder, basados en datos reales, cinco de las preguntas más importantes que surgen en el día a día durante el manejo de los pacientes trasplantados


There is a high expectation generated by the rapid expansion of SARS-CoV2 (Severe Acute Respira-tory Syndrome related to Coronavirus 2), which is the etiological agent of the Coronavirus Infectious Disease 2019, COVID-19. As an emerging disease, little is known about its behavior in humans, which generates multiple questions when making decisions in clinical practice. So far, the strategies to face this pandemic are based on the experience of the countries that have been the epicenter of the infectious outbreak and on the evidence collected during the management of other past coronavirus infections such as (SARS-CoV in 2002 and MERS-CoV in 2012). The lack of unified and robust information has given rise to speculation and assumptions primarily related to the care and management of COVID-19 in populations considered at high risk of infection, such as chronically immunosuppressed patients after transplantation. Beyond giving the opinion from the authors, this narrative review tries to organize the documents published so far and to answer five of the most critical questions that arise every day during the management of transplant patients based on real data


Subject(s)
Humans , Coronavirus Infections , Transplantation , SARS Virus , Pandemics
9.
Transplant Proc ; 52(9): 2596-2600, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-431194

ABSTRACT

BACKGROUND: Although hospital systems have largely halted elective surgical practices in preparing their response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, transplantation remains an essential and lifesaving surgical practice. To continue transplantation while protecting immunocompromised patients and health care workers, significant restructuring of normal patient care practice habits is required. METHODS: This is a nonrandomized, descriptive study of the abdominal transplant program at 1 academic center (University of California, San Francisco) and the programmatic changes undertaken to safely continue transplantations. Patient transfers, fellow use, and patient discharge education were identified as key areas requiring significant reorganization. RESULTS: The University of California, San Francisco abdominal transplant program took an early and aggressive approach to restructuring inpatient workflows and health care worker staffing. The authors formalized a coronavirus disease 2019 (COVID-19) transfer system to address patients in need of services at their institution while minimizing the risk of SARS-CoV-2 in their transplant ward and used technological approaches to provide virtual telehealth where possible. They also modified their transplant fellow staffing and responsibilities to develop an adequate backup system in case of potential exposures. CONCLUSION: Every transplant program is unique, and an individualized plan to adapt and modify standard clinical practices will be required to continue providing essential transplantation services. The authors' experience highlights areas of attention specific to transplant programs and may provide generalizable solutions to support continued transplantation in the COVID-19 era.


Subject(s)
Coronavirus Infections , Pandemics , Pneumonia, Viral , Transplantation/standards , Workflow , Betacoronavirus , COVID-19 , Humans , Patient Care/methods , Patient Care/standards , SARS-CoV-2 , San Francisco , Transplantation/methods
10.
Transpl Infect Dis ; 22(5): e13327, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-260203

ABSTRACT

Coronavirus disease 2019 (COVID-19) pandemic poses an increasing challenge for transplant community. Aggressive management measures are conductive to improve compliance and to lower the risk of intra-hospital infection. In this Personal Viewpoint essay, we shared experiences about management strategies of transplant patients outside hospital amid the epidemic. With the aid of Cloud Clinic service and telemedicine care, transplant patients could be regularly followed up and get medical consultation online. Furthermore, personal health education and mental health assistance are enrolled in our practice.


Subject(s)
Aftercare/organization & administration , COVID-19/prevention & control , Outpatient Clinics, Hospital/organization & administration , Telemedicine/organization & administration , Transplant Recipients , Aftercare/methods , Aftercare/standards , COVID-19/epidemiology , COVID-19/transmission , COVID-19/virology , China , Cloud Computing , Communicable Disease Control/organization & administration , Communicable Disease Control/standards , Humans , Immunocompromised Host , Opportunistic Infections/immunology , Opportunistic Infections/prevention & control , Outpatient Clinics, Hospital/standards , Pandemics/prevention & control , Patient Compliance , SARS-CoV-2/pathogenicity , Specialties, Surgical/organization & administration , Telemedicine/methods , Telemedicine/standards , Transplantation/adverse effects
11.
Bone Marrow Transplant ; 55(10): 1900-1905, 2020 10.
Article in English | MEDLINE | ID: covidwho-99943

ABSTRACT

Italy is the second exposed country worldwide, after China, and Lombardia is the most affected region in Italy, with more than half of the national cases, with 13% of whom being healthcare professionals. The Clinica Pediatrica Università degli Studi di Milano Bicocca is a general pediatric and hematology oncology and transplant center embedded within the designated COVID-19 general Hospital San Gerardo in Monza, located in Lombardia, Italy. Preventive and control measures specifically undertaken to cope with the emergency within hemato-oncology, transplant, and outpatient unit in the pediatric department have been described. Preliminary COVID-19 experiences with the first Italian pediatric hemato-oncology patients are reported. The few available data regarding pediatrics and specifically hemato-oncological patients are discussed. The purpose of this report is to share pediatric hemato-oncology issues encountered in the first few weeks of the COVID-19 outbreak in Italy and to alert healthcare professionals worldwide to be prepared accordingly.


Subject(s)
Coronavirus Infections/epidemiology , Hematology/organization & administration , Infection Control/methods , Medical Oncology/organization & administration , Pediatrics/organization & administration , Pneumonia, Viral/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Betacoronavirus , COVID-19 , Child , Child, Preschool , Coronavirus Infections/prevention & control , Female , Hospitals , Humans , Infant , Infant, Newborn , Italy/epidemiology , Male , Middle Aged , Neoplasms/complications , Outpatients , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , SARS-CoV-2 , Stem Cell Transplantation , Transplantation , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL